A000105 Stock Overview

Manufactures and sells prescription drugs, over-the-counter drugs, veterinary drugs, and household goods in South Korea and internationally. More details

A000105 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	3/6
Past Performance	5/6
Financial Health	5/6
Dividends	0/6

Rewards

Earnings are forecast to grow 20.37% per year

Earnings grew by 88% over the past year

Risk Analysis

No risks detected for A000105 from our risk checks.

My Notes

Capture your thoughts, links and company narrative

Yuhan Corporation Competitors

SK Biopharmaceuticals

KOSE:A326030

₩8.2t

Hanmi Pharm

KOSE:A128940

₩3.4t

Daewoong Pharmaceutical

KOSE:A069620

₩1.4t

ST PharmLtd

KOSDAQ:A237690

₩1.8t

Price History & Performance

Summary of share price highs, lows and changes for Yuhan
Historical stock prices
Current Share Price	₩100,500.00
52 Week High	₩207,000.00
52 Week Low	₩56,000.00
Beta	0.60
1 Month Change	-3.09%
3 Month Change	-32.23%
1 Year Change	58.27%
3 Year Change	70.05%
5 Year Change	139.86%
Change since IPO	2,387.38%

Recent updates

Shareholder Returns

	A000105	KR Pharmaceuticals	KR Market
7D	-1.5%	-0.5%	-1.9%
1Y	58.3%	0.8%	-9.5%

Return vs Industry: A000105 exceeded the KR Pharmaceuticals industry which returned 0.8% over the past year.

Return vs Market: A000105 exceeded the KR Market which returned -9.5% over the past year.

Price Volatility

Is A000105's price volatile compared to industry and market?
A000105 volatility
A000105 Average Weekly Movement	7.3%
Pharmaceuticals Industry Average Movement	5.5%
Market Average Movement	6.6%
10% most volatile stocks in KR Market	12.8%
10% least volatile stocks in KR Market	3.3%

Stable Share Price: A000105 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: A000105's weekly volatility (7%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1926	1,994	Wook-Je Cho	www.yuhan.co.kr

Yuhan Corporation manufactures and sells prescription drugs, over-the-counter drugs, veterinary drugs, and household goods in South Korea and internationally. It also manufactures and sells animal feed and health functional food. The company was founded in 1926 and is headquartered in Seoul, South Korea.

Yuhan Corporation Fundamentals Summary

How do Yuhan's earnings and revenue compare to its market cap?
A000105 fundamental statistics
Market cap	₩8.63t
Earnings (TTM)	₩165.69b
Revenue (TTM)	₩2.01t

52.2x

P/E Ratio

4.3x

P/S Ratio

Is A000105 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A000105 income statement (TTM)
Revenue	₩2.01t
Cost of Revenue	₩1.33t
Gross Profit	₩674.23b
Other Expenses	₩508.54b
Earnings	₩165.69b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	2.21k
Gross Margin	33.56%
Net Profit Margin	8.25%
Debt/Equity Ratio	12.1%

How did A000105 perform over the long term?

See historical performance and comparison

Dividends

0.4%

Current Dividend Yield

20%

Payout Ratio

Does A000105 pay a reliable dividends?

See A000105 dividend history and benchmarks

When do you need to buy A000105 by to receive an upcoming dividend?
Yuhan dividend dates
Ex Dividend Date	Dec 27 2024
Dividend Pay Date	Mar 31 2025
Days until Ex dividend	0 days
Days until Dividend pay date	94 days

Does A000105 pay a reliable dividends?

See A000105 dividend history and benchmarks

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/26 02:37
End of Day Share Price	2024/12/26 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Yuhan Corporation is covered by 40 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Young-Ah Han	BofA Global Research
Seohyun Lee	Citigroup Inc
Hyonseok Kim	CLSA

Yuhan KOSE:A000105 Stock Report